Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30639492 | 0.98 | HDAC6 (0.41) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL28515816 | 0.88 | HDAC6 (0.38) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL8223754 | 0.87 | HDAC6 (0.40) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL17309612 | 0.85 | ALDH1A1 (0.40) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL19292207 | 0.84 | ALDH1A1 (0.43) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL31110583 | 0.84 | ALDH1A1 (0.43) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL31240161 | 0.84 | ALDH1A1 (0.43) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL9431001 | 0.84 | ALDH1A1 (0.43) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL31211601 | 0.84 | ALDH1A1 (0.43) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL30864371 | 0.84 | ALDH1A1 (0.43) | HDAC6HDAC1HDAC2HDAC3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715167-A | Lipid-substituted amino 1, 2-and 1, 3-diol compounds as modulators of TLR2 dimerization | 神经孔疗法股份有限公司 | 2019-05-03 | — | — | CN | claimed |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| CN-104105691-A | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC | 2014-10-15 | — | — | CN | claimed |
| US-20250382264-A1 | HETEROCYCLE-CONTAINING AMINO ACID COMPOUND AND COMPLEX | AICHI STEEL CORPORATION (JP) | 2025-12-18 | — | — | US | disclosed |
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4565585-A1 | COMPOUNDS FOR MODULATING RET PROTEIN | Bristol-Myers Squibb Company (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-119504710-A | PROTACs compound for targeted degradation of PRMT5 and application thereof | 昆明医科大学 | 2025-02-25 | — | — | CN | disclosed |
| EP-4501909-A1 | HETEROCYCLE-CONTAINING AMINO ACID COMPOUND AND COMPLEX | Aichi Steel Corporation (JP) | 2025-02-05 | — | — | EP | disclosed |
| CN-118063391-A | Pyrimidine compound and synthetic method and application thereof | 云南民族大学 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024030968-A1 | COMPOUNDS FOR MODULATING RET PROTEIN | BRYSTOL-MYERS SQUIBB COMPANY (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| CN-1068333-A | Has hydrazine analog derivative of pharmacologically active and preparation method thereof | CIBA GEIGY AG (CH) | 1993-01-27 | — | — | CN | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| CN-1035283-A | Process for producing tert-butyl 3-oxobutyrate and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1989-09-06 | — | — | CN | disclosed |
| EP-0329606-A2 | Antibiotics from myxocuccos | CIBA-GEIGY AG (CH) | 1989-08-23 | — | — | EP | disclosed |
| EP-0173226-B1 | PROCESS FOR THE PREPARATION OF BETA-FORMYL PROPIONIC ACID TERT.-BUTYL ESTER | Ruhrchemie Aktiengesellschaft (DE) | 1988-05-25 | — | — | EP | disclosed |
| EP-0173226-B1 | PROCESS FOR THE PREPARATION OF BETA-FORMYL PROPIONIC ACID TERT.-BUTYL ESTER | Ruhrchemie Aktiengesellschaft (DE) | 1988-05-25 | — | — | EP | disclosed |
| EP-0173226-A1 | Process for the preparation of beta-formyl propionic acid tert.-butyl ester | Ruhrchemie Aktiengesellschaft (DE) | 1986-03-05 | — | — | EP | disclosed |
| EP-0173226-A1 | Process for the preparation of beta-formyl propionic acid tert.-butyl ester | Ruhrchemie Aktiengesellschaft (DE) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382264-A1 | HETEROCYCLE-CONTAINING AMINO ACID COMPOUND AND COMPLEX | NR2C2, NR3C2, NPR1 | HDAC6 2365/4885HDAC1 261/4885HDAC2 413/4885 |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | STING1, PDCD1LG2, CD274 | HDAC6 2529/4885HDAC1 3667/4885HDAC2 3806/4885 |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | MRGPRX1, MRGPRX2, AGTR1 | HDAC6 1631/4885HDAC1 1757/4885HDAC2 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.